Search results
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoNektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript May 9, 2024 Nektar Therapeutics...
Understanding Rosacea: 10 Natural Ways to Soothe and Calm Red, Irritated Skin
Best Life· 5 days agoRosacea is an inflammatory skin condition that can cause a range of uncomfortable symptoms. Many...
13 Penny Stocks with Insider Buying in 2024
Insider Monkey via Yahoo Finance· 2 days agoIn this article, we will take a detailed look at the 13 Penny Stocks with Insider Buying in 2024. If you want to skip our detailed analysis and see the...
Earnings call: Almirall targets leadership in medical dermatology with Q1 growth By Investing.com
Investing.com· 16 hours agoAlmirall, the pharmaceutical company specializing in medical dermatology, outlined a solid start to...
BofA bullish on Apogee stock, sees significant market growth potential By Investing.com
Investing.com· 4 days agoFriday, BofA Securities initiated coverage on Apogee (NASDAQ:APOG) Therapeutics Inc (NASDAQ:APGE)...
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Pharmaceutical Technology via Yahoo Finance· 24 hours agoMany patients also have other type 2 inflammatory diseases such as asthma. Dupixent was first...
New treatment could reverse hair loss caused by autoimmune skin disease alopecia areata
Medical Xpress· 5 days agoThe team has developed a microneedle patch that can be painlessly applied to the scalp and releases...
vTv Therapeutics (NASDAQ:VTVT) Lowered to Sell at StockNews.com
ETF DAILY NEWS· 7 hours agoStockNews.com cut shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) from a hold rating to a sell rating in a research report report published on Monday. vTv Therapeutics Trading Down 0.3 ...
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European...
Benzinga· 1 day agoPositive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines,
Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
GuruFocus.com via Yahoo Finance· 6 days agoThere are inherent risks in drug development, highlighted by the need for reevaluation of ATI 2138's indication selection, which can lead to delays and increased costs. The competitive landscape ...